SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-038533
Filing Date
2024-03-26
Accepted
2024-03-25 18:18:15
Documents
15
Period of Report
2024-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm249709d1_8k.htm   iXBRL 8-K 24651
2 EXHIBIT 99.1 tm249709d1_ex99-1.htm EX-99.1 107762
6 GRAPHIC tm249709d1_ex99-1img001.jpg GRAPHIC 6342
  Complete submission text file 0001104659-24-038533.txt   326002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20240325.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20240325_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20240325_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT tm249709d1_8k_htm.xml XML 3510
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 24780429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)